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Abstract
Background and Aims: Extraintestinal manifestations are reported to occur in up to
45% of inflammatory bowel disease (IBD) patients during the course of disease. It is
unknown whether colectomy reduces the rate of de novo extraintestinal manifes-
tations (EIMs) or impacts on severity of EIMs following a parallel versus indepen-
dent disease course from underlying IBD.
Methods: Using data from the Swiss Inflammatory Bowel Disease Cohort Study we
aimed to analyse the course of EIMs in ulcerative colitis (UC) and Crohn’s disease
(CD) patients undergoing colectomy during the cohort’s prospective follow‐up.
Results: One hundred and twenty‐one IBD patients (33 CD, 81 UC and seven un-
classified) underwent colectomy during prospective follow‐up in the Swiss Inflam-
matory Bowel Disease Cohort Study.Within the 114 patients with UC or CD any EIM
was reported in40 (nineCDand31UC)patients. Activity of EIMs ceasedentirely after
colectomy in 21 patients (52.5%). Complete cessation of EIM after colectomy was
higher in patients with UC versus CD with 58.1% versus 33.3%. After colectomy, 29
out of the 114patients (25.4%) experienced anyEIM. Two thirds of these (19 patients)
represented persisting EIMs, while in one third (10 patients) EIM represented a de‐
novo event after colectomy. Overall, 13.5% of IBD patients developed a de‐novo
EIM after colectomy.
Conclusions: In IBD patients undergoing colectomy, EIMs present prior to surgery
will persist in about half of patients. Complete cessation of EIM after colectomy may
be less common in CD than in UC. In patients who never experienced EIMs prior to
colectomy de‐novo manifestations thereafter should be expected in up to one in
seven patients.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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INTRODUCTION
Of the two main forms of inflammatory bowel disease (IBD), ulcer-
ative colitis (UC) appears to be slightly more common than Crohn’s
disease (CD) and the incidence and prevalence of both conditions
was reported to be rising in the western world and developing
countries as well as Asia.1–3 In recent years, the treatment of IBD
has progressively increased in complexity with a substantial increase
in available medical treatment options. This increase in available
mechanisms of action for the treatment of UC and CD has been
associated with a reduced frequency of colectomy, traditionally
considered the last treatment option in refractory UC. In the 1990s
the fraction of UC patients undergoing colectomy within 10 years
after diagnosis ranged between 20% and 45%, but dropped to less
than 10% according to recent studies from Europe4–6 and North
America.7
In contrast to UC, where total proctocolectomy represents
the surgical strategy of choice, numerous surgical techniques for
CD are available, depending on segmental intestinal involvement,
extension of disease, presence of local penetrating complications
as well as the surgeon’s or patient’s preference.8,9 Due to better
functional results of segmental colectomy,10 total colectomy in CD
is reserved for extensive colonic involvement including a large
proportion of the colon and the rectum or severe to fulminant
disease activity.8,11
In a considerable fraction of IBD patients the disease is not
limited to the colon and/or small bowel but also affects other organ
systems including joints, skin, liver and eyes, subsumed under the term
extraintestinal manifestations (EIMs). Between 10% and 45%12–14 of
IBD patients suffer from EIM, mostly arthropathies, but also aphthous
stomatitis, primary sclerosing cholangitis (PSC), uveitis, erythema
nodosum and pyoderma gangrenosum. Currently, knowledge on the
pathogenesis of EIM remains limited.15,16 In around a quarter of pa-
tients EIM manifest before diagnosis of IBD,17 whereas in others first
presentation of EIM follows IBD diagnosis by several years.18 The
clinical course of some EIM, for example, pauciarticular peripheral
arthritis14 (type I), was reported to follow a course of disease largely
parallel to the disease activity of the underlying IBD, in contrast to
others, such as PSC, ankylosing spondylitis or polyarticular arthritis14
(type II), with a rather independent course of disease.19,20
EIM may significantly increase the burden19,21 of disease and
EIM also have been associated with an increased need for cortico-
steroids, immunosuppressives, biologics as well as risk of colec-
tomy.4,22 In a Japanese study, preoperative EIM have also been
shown to be an independent risk factor for postoperative complica-
tions and chronic pouchitis.23
Considering the relation of EIM and course of IBD, one might
assume that the activity of those EIM, that are known to frequently
run parallel to the underlying IBD would considerably improve or
even entirely cease in patients having undergone total colectomy. In
contrast, no such beneficial effect subsequent to colectomy would be
expected in EIM that run independently from the course of IBD.
Interestingly, literature on EIM and colectomy in IBD currently re-
mains scarce, with so far only a single prior study in UC patients to the
best of our knowledge.24 In this retrospective study from the US, PSC
and ocular manifestations remained unchanged in patients with total
colectomy with pouch, ileostomy or ileorectostomy, whereas all other
EIM showed a variable, although rather favourable disease course
subsequent to colectomy.
Therefore, the aim of our study was to evaluate the course of
EIM in patients with CD and UC undergoing colectomy using the
prospectively collected data from the Swiss IBD Cohort.
MATERIALS AND METHODS
Swiss IBD‐Patients
The Swiss IBD Cohort study (SIBDCS) was approved by local au-
thorities and ethics committees and launched in 2006; cumulatively
Key summary
Established knowledge:
� The burden of extraintestinal manifestation (EIM) in in-
flammatory bowel disease (IBD) is substantial, affecting
up to 45% of patients with subsequent higher need for
steroids and advanced treatment options.
� Some EIM as for example peripheral arthropathy usually
run a course parallel to underlying IBD, while others (e.g.,
primary sclerosing cholangitis) rather reveal to be
independently.
� Very scarce evidence suggests that colectomy might
positively influence EIM in ulcerative colitis (UC), spe-
cifically those with a parallel course of activity.
New findings:
� Established EIM prior to colectomy will significantly
decrease thereafter, nevertheless may persist in almost
every second patients.
� These results hold true for both, UC as well as Crohn’s
disease (CD), while complete cessation of EIM tends to
be more common in UC as compared to CD.
� De‐novo EIM after colectomy occurs in up to one out of
seven patients.
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collecting data of approximately 4000 IBD patients in Switzerland.
Several institutions including university hospitals, regional hospitals
and private practices located all over Switzerland are responsible for
the recruitment of patients with the University of Lausanne as the
coordinating‐ and database‐centre. Retrospective data have been
obtained from patient charts since diagnosis regardingmedical history
of IBD prior to inclusion into the SIBDCS (retrospective collection) and
thereafter a prospective collection of comprehensive clinical data
during medical visits at inclusion and annual follow‐up by gastroen-
terologist and study coordinators using standardized reporting forms.
In addition, patients are directly interrogated at inclusion and annual
follow‐up independent from any health care professional (i.e., pure
patient‐reported outcome measurement) by specific and also stan-
dardized patient questionnaires. All forms are then transmitted to
Lausanne for validation and entry into the database.25,26
Amongst others, the SIBDCS collects specific information about
IBD, disease activity, quality of life and EIMs. Approval from the local
ethic committees for the SIBDCS was provided in 2005 (KEK‐ZH
1316) and renewed in 2018 (2018‐02068). All participants provide
an informed consent form at the time of inclusion into the SIBDCS.
For this study, only patients with at least one visit before and one
visit after partial or total colectomy during the prospective follow‐up
in the SIBDCS from 2006 until October 2020 were included into the
analysis. Accordingly, data on EIM and medication before colectomy
was available for the analysed patients. Therefore, patients with
colectomy before inclusion into the SIBDCSwere excluded due to lack
of robust and prospectively obtained data before colectomy.
Furthermore, we decided to exclude patients with unspecified IBD
(IBDu) due to small sample size, allowing pure subgroup analysis for
CU and CD. In contrast, no subgroup analysis could be performed with
regards to the primary indication for colectomy, that is, disease re-
fractory to medical therapy versus dysplasia/malignancy. As outlined
in detail in a previous analysis of SIBDCS by our group,4 refractory
disease by far represents the most frequent indication in the vast
majority of patients undergoing colectomy (only 4.8% and 7.1%,
respectively due to colorectal cancer and dysplasia).
Statistics
Data was analysed using Stata (StataCorp, College Station, TX 77845
Version 16.0) with descriptive statistics, bivariate and multivariate
analysis. Quantitative variables were summarized as mean, standard
deviation and range if they were normally distributed. Non‐normally
distributed variables were summarized as median, interquartile range
(IQR) and range. Chi‐Square test was used to test differences be-
tween groups of categorical variables. Congruent with standard
statistical procedures Fisher exact test was used for small sample size
comparisons, that is, less than 5 subjects per group. Furthermore,
propensity score matching was performed to investigate the indi-
vidual effect of different parameters. Propensity score matching was
computed with EIM only after colectomy and EIM only before
colectomy as dependent variables as well as age at colectomy,
disease duration, gender and refractory disease as explanatory var-
iables. Due to the sample size, it was not possible to include more
explanatory variables into the propensity score analysis.
RESULTS
Amongst a total of 3620 IBD patients in the SIBCS (1549UC, 1941 CD
and 130 IBDU) 416 patients underwent colectomy. Out of these, 294
(70.7%) had a colectomy prior to inclusion into the SIBDCS and in 121
(29.3%) patients, colectomy was performed during the prospective
follow‐up period within the SIBDCS. Of the 121 patients undergoing
colectomy during SIBDCS’s prospective follow‐up, 81 (67.3%) were
diagnosed with UC, 33 (27%) with CD and 7 (5.7%) with IBD unclas-
sified. Only patients who underwent colectomy during the prospective
SIBDCS follow‐up and who were diagnosed with either UC or CD (i.e.,
not IBDu) were considered for further analyses in our study (Figure 1).
The average patient undergoing colectomy in the SIBDCS was
40 years of age and had the disease diagnosed 10 years ago (Table 1).
The median length of follow‐up in the cohort was 5.11 years (IQR 6.5,
range 0–13 years). Significantly more patients with CD were
smokers. Furthermore, CD patients had a significantly higher rate of
current or past therapy with anti‐tumornecrosis factor or immuno-
modulatory medication compared to UC. Looking at medical thera-
pies received after colectomy, we did not observe any significant
differences between patients with versus without EIM. The surgical
types of colectomy are displayed in Table 2.
F I GUR E 1 Flowchart. This figure displays a flow chart of
patient selection in absolute numbers in this study
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NoEIMhadbeenpresentbefore colectomy in74 (64.9%)outof the
114 patients. Amongst these 74 patients, 10 (UC n = 6, 7.4%, CD n= 4,
12.1%) developed de‐novo EIM after colectomy, that is 13.5%. The
remaining 40 patients (35.1% of total, UC n = 31, 38.3% of total, CD
n = 9, 27.3% of total) undergoing colectomy had experienced at least
one EIM before colectomy. Significantly more patients with UC
compared to CD patients experienced a cessation of previously exist-
ing EIM after colectomy (52.5% cessation in IBD overall, UC n = 18,
58.1% cessation, CD n = 3, 33.3% cessation, p < 0.001, Figure 2).
However, EIMpersistedoverall in almostevery secondpatient (47.5%).
After colectomy, any EIM was present in 29 out of 114 patients
(25.4%). Nineteen out of these 29 patients (65.5%) presented with
persisting EIM despite colectomy. In contrast, in the other 10 EIM
with EIM subsequent to colectomy, a de‐novo appearance of EIM
after colectomy was observed. Using a Kaplan–Meier curve, we
observed that patients with EIM at the time of colectomy still
harbour a 50% chance of persistent or recurrent EIM even 8 years
thereafter. Importantly, freedom from EIM at colectomy was asso-
ciated with sustained freedom from any EIM 8 years after colectomy
in almost 75% of patients (Figure 3).
TAB L E 1 Characteristics of patients, both UC and CD, that underwent colectomy during prospective follow‐up in the SIBDCS, comparing
patients with EIM and without after colectomy. Immunomodulators used included Cyclosporin, Tacrolimus, Azathioprine, 6‐Mercaptopurine,
Methotrexate and Deflazacort, furthermore 5‐ASA. SD is shown for mean, IQR for median
Patient characteristics Patients with EIM after colectomy Patients without EIM after colectomy p‐value
Numbers n 29 85
Female n (%) 14 (48.3%) 32 (37.7%) 0.314
Mean (SD) age at colectomy [years]: 41 (9), range (22– 65) 40 (15.5), range (8 – 81) 0.316
Median (IQR) disease duration at colectomy [years] 11 (8.2), range (2 ‐ 32) 8.4 (10), range (1.5‐ 36) 0.165
Type of IBD n (%)
Ulcerative colitis 19 (65.5%) 60 (70.6%) 0.609
Crohn’s disease 10 (34.5%) 25 (29.4%)
Smoking status at colectomy n (%)
Yes 4 (13.8%) 8 (9.4%) 0.507
No 25 (86.2%) 77 (90.6%)
Current therapy at colectomy n (%)
5‐ASA 5 (17.2%) 22 (25.9%) 0.45
Steroid 3 (10.3%) 17 (20%) 0.238
Immunomodulators 4 (13.8%) 14 (16.5%) 0.733
Anti TNF 10 (34.5%) 14 (16.5%) 0.04
Vedolizumab 1 (3.5%) 1 (1.2%) 0.421
Past therapy n (%)
5‐ASA 22 (75.9%) 64 (75.3%) 0.951
Steroid 27 (93.1%) 81 (95.3%) 0.648
Immunomodulators 23 (79.3%) 68 (80%) 0.936
Anti‐TNF 19 (65.5%) 59 (69.4%) 0.697
Vedolizumab 3 (10.3%) 10 (11.8%) 0.835
Therapy after colectomya n (%)
5‐ASA 2 (7%) 5 (5.9%) 0.844
Steroid 3 (10.3%) 6 (7.1%) 0.571
Immunomodulators 3 (10.3%) 6 (7.1%) 0.571
Anti TNF 1 (3.5%) 6 (7.1%) 0.484
Vedolizumab 1 (10.3%) 1 (11.8%) 0.421
Abbreviations: 5‐ASA, aminosalicylic acid; anti‐TNF, anti‐tumornecrosis factor; CD, Crohn’s disease; EIM, extraintestinal manifestation; IQR,
interquartile range; SD, standard deviation; SIBDCS, Swiss IBD Cohort study; UC, ulcerative colitis.
aCumulative treatments during SIBDCS follow‐up up to 5 years after colectomy; statistical tests used: Chi2 and Kruskal Wallis.
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Looking separately at UC and CD patients, prior to colec-
tomy 31 out of 81 patients in UC (38.3%) and 9 out of 33 in
CD (27.3%) suffered from EIM. After colectomy however, only 13
UC and 6 CD revealed any EIM, corresponding to a significant
reduction of 58.1% and 33.3% after colectomy in UC and CD
(p = 0.002 and p = 0.005).
With regards to specific EIM, peripheral arthritis/arthralgia by far
represented the most frequently reported EIM, accounting for 75.6%
of all reported EIM, followed by aphthous oral ulcers (22.0%; Table 3).
By means of propensity score matching we did not identify fac-
tors that could predict occurrence of de‐novo EIM or cessation of
EIM. Specifically, neither age at colectomy, gender nor disease
duration at colectomy were associated with occurrence or cessation
of EIM after colectomy (see Tables S4 & S5).
DISCUSSION
Having analysed the course of EIM in IBD patients undergoing
colectomy we could obtain several important findings. First, EIM
that were present before surgical intervention will persist in about
half of patients after surgery in IBD. Second, the effect of surgery
appears to be more favourable in UC than in CD, with only 41.9%
in UC persistently suffering from EIM after colectomy compared to
67% in CD. Third, absence of EIM prior to surgery unfortunately
does not imply continuous freedom from EIM after surgery. Indeed,
up to one in seven IBD patients developed de‐novo EIM after
colectomy (again, there was a numerically but not statistically sig-
nificant difference in favour for UC vs. CD with 16% vs. 21% de‐
novo EIM, respectively).
In contrast to recent large‐scale registry data (Algaba, Guerra
et al. based on the ENEIDA registry21) from Spain, where several risk
factors for EIM have been described, we did not identify gender,
disease duration at colectomy or age at colectomy as risk factors
associated with cessation or de‐novo development of EIM after
colectomy. This difference might be due to the lower patient number
in our study. Of note, the most frequently reported EIM was
peripheral arthritis/arthralgia, independent of CD or UC. To this date
it remains unclear, whether distinctive EIM, such as for example
peripheral arthritis Type 1 (pain in <6 joints, mostly large, weight‐
bearing joints) with classically a course of activity in parallel with
course of underlying IBD have a different course of activity after
colectomy than those EIM with a well‐recognized independent
course of activity from underlying IBD.14,18–20 Interestingly, accord-
ing to our data, rates of peripheral arthritis appear to substantially
decline after proctocolectomy. These data support the results ob-
tained by Goudet et al.24 where a complete resolution of arthritis in
almost 41%–59% of patients after surgical intervention in UC pa-
tients was found. Considering EIM with a known independent course
of activity from underlying IBD14,19,20 PSC might be the most
prominent example. In our study, in all patients with established PSC
prior colectomy, PSC persisted thereafter—without any exception. Of
note, none of the CD patients in our study was diagnosed with PSC.
These findings are also in line with the study from Goudet et al.24
where aggravation or persistent PSC was reported in 86% of UC
patients following colectomy.
Our study indicates, that in the process of evaluating an indica-
tion for colectomy and carefully balancing the pros and cons in
meticulous discussions between patient and physicians, EIM should
also represent one piece of the puzzle in the complex decision‐
making process. Importantly, the potential effect of colectomy on
the course of activity of any given EIM present prior to colectomy
may be extremely variable and heterogenous. Depending on the
specific type of EIM, rates of EIM disappearance after colectomy may
be as high as 72% (peripheral arthritis in UC) or as low as 0% (PSC in
UC). Hence presence of any EIM and the potential subsequent course
of EIM after colectomy should be discussed with the patient to set
realistic expectations for the future course of disease after surgery.
Unfortunately, and as mentioned previously, the literature basis for
such a discussion yet is extremely scarce and further studies
including more patients with a vigorous follow‐up focussing on a
dedicated assessment of EIM in line with our current work will be
important.
Interestingly, our data indicate that despite beneficial effects of
colectomy regarding EIM in both, CD and UC, the net benefit of
colectomy appears to be stronger in UC as opposed to CD. Our study
did not identify risk factors for cessation or development of de‐novo
EIM before or after colectomy. Age at colectomy as well as disease
duration at colectomy or gender did not influence the course of EIM.
We speculate that this discrepancy might be due to the fact, that CD
represents a disease state with a more systemic connotation, and
therefore the act of a purely mechanical removal of the inflamed
colon may be associated with less beneficial disease‐modifying
effects.
Our study has several strengths and limitations. A strength of
our study is the highly relevant topic, enlightening hitherto ill‐
defined features of EIM after surgical interventions which up to
now have only been investigated in a single study.24 Moreover, this
study was limited to UC patients, whereas our analysis also
considered CD patients. Limitations include the small sample size
TAB L E 2 This table displays the surgical types of colectomy
used in numbers. The total number of surgeries exceeds the total
number of patients (therefore cumulative percentages exceed
100%), since multiple surgical interventions have been performed
on certain patients. Percentages are given in relation to the total






Total proctocolectomy 64 (79.0) 1 (3.0)
Subtotal colectomy 16 (19.8) 7 (21.2)
Right colectomy 3 (3.7) 15 (45.5)
Left colectomy 5 (6.2) 12 (36.4)
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease;
UC, ulcerative colitis.
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F I GUR E 2 Frequency of extraintestinal manifestation (EIM) before and after colectomy. Pie charts depicting percentage of patients with
EIM before and after colectomy in inflammatory bowel disease (IBD) overall (upper row), ulcerative colitis (UC; middle row) and Crohn’s
disease (CD; lower row)
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since despite the rather high number of available IBD patients
within the SIBDCS (around 4000 patients), colectomy represents a
rather rare event. Due to improvements in medical treatment,
colectomy rates might continue to decline in the future, further
complicating the gathering of data of larger number of patients and
multi‐centre efforts will be required. Another important limitation
refers to the limited standardization and lack of validated outcome
measures on how course of EIM in IBD patients are recorded. This
limitation refers to prospective and retrospective investigations on
EIM in IBD in general and indeed also to our study in specific.
Another limitation concerns postoperative disease activity. Unfor-
tunately, there are no validated scores to assess disease activity
after total proctocolectomy, making it difficult to compare pre‐and
postoperative disease activity. Something similar applies to pou-
chitis, presumably the most frequent and relevant complication of
total colectomy. In our investigation, data on pouchitis are not
recorded in a standardized fashion in the SIBDCS. However, the
vast majority of patients suffers from only one or a small number of
distinctive episodes of pouchitis, These patients only undergo
endoscopic and histologic evaluation in a minority of cases, which
would be a prerequisite to determine the pouchitis disease activity
index.27 Short‐term antibiotic treatment is frequently associated
with a prolonged freedom from further episodes of pouchitis, yet
patients in Switzerland rather receive a course of short‐term anti-
biotics from their general practitioners (GP) than from their
gastroenterologist. The primary care of GPs and prescription of
antibiotics by the GP might be unique in the Swiss healthcare
system, whereas in other countries those patients might rather be
seen directly by a gastroenterologist. However, since pouchitis re-
solves in about 95% of cases, we do not consider that to be a major
concern.28 Finally, our study has a non‐interventional study design
but due to the specific study question, neither a double‐blind nor
randomized controlled study design will be feasible.
In conclusion our data indicate that complete cessation of EIM
after colectomy occurs in about every second patient overall and
may be less common in CD than in UC patients. Furthermore,
rates of complete cessation after colectomy are highly variable
according to the type of EIM with best prospects for peripheral
arthritis.
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F I GUR E 3 Depicting a Kaplan–Meier curve. Reading example:
The probability of developing new extraintestinal manifestation
(EIM) 10 years after colectomy when having EIM at colectomy is
approximately 0.25 and the probability of not developing new EIM
when not having EIM at colectomy is approximately 0.57 at
10 years
TAB L E 3 Extraintestinal manifestation (EIM) in ulcerative
colitis and Crohn’s disease before and after colectomy. Of note,
few patients had more than one EIM. No cases of pyoderma
gangrenosum were reported. The percentages are given as














Total EIM 40 (35.1) 19 (16.7) 10 (8.8)
Peripheral arthritis 30 (26.3) 13 (11.4) 8 (7.0)
Uveitis 00 (0) 00 (0) 2 (1.8)
Erythema nodosum 1 (0.9) 00 (0) 00 (0)
Aphthous oral ulcers 8 (7.0) 2 (1.8) 1 (0.9)
Ankylosing spondylitis 5 (4.4) 2 (1.8) 1 (0.9)
Primary sclerosing
cholangitis
4 (3.5) 4 (3.5) 2 (1.8)
Primary sacroiliitis 00 (0) 00 (0) 1 (0.9)
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